Releases - Bluefish Pharmaceuticals AB

View:
 

Found press releases

 

Interim report January-March 2013

5/6/2013 10:31 AM EST
- Net sales amounted to SEK 46.0 million (42.2) - EBITDA was SEK -1.5 million (-6.8) - Earnings per share totaled SEK -0.13 (-0.29) before dilution HIGHLIGHTS Significant improvement in profitability - Gross margin increased by 5 percentage points - Operating costs reduced by 7% Positive cash flow from decline in inventory - Improvements in supply chain and logistics has reduced inventory levels - Cash flow from...

Year-end Report 2012

2/28/2013 7:04 AM EST
JANUARY – DECEMBER 2012 - Net sales amounted to SEK 162.3 million (145.2) - EBITDA was SEK -52.7 million (-20.1) - Earnings per share totaled SEK -1.50 (-1.09) before dilution OCTOBER – DECEMBER 2012 - Net sales amounted to SEK 36.9 million (41.6) - EBITDA was SEK -25.5 million (-6.6) - Earnings per share totaled SEK -0.53 (-0.33) before dilution HIGHLIGHTS Financial performance hurt by one-off items - Net sales...

Interim report January - September 2012

11/14/2012 2:20 AM EST
JANUARY – SEPTEMBER 2012

· Net sales amounted to SEK 125.5 million (103.7)
· EBITDA was SEK -27.3 million (-13.5)
· Earnings per share totaled SEK -0.94 (-0.75) before dilution

JULY – SEPTEMBER 2012

· Net sales amounted to SEK 44.7 million (38.7)
· EBITDA was SEK -7.1 million (-4.3)
· Earnings per share totaled SEK -0.24 (-0.27) before dilution

HIGHLIGHTS

Continued net sales growth
- Net sales growth in...

Interim report January - June 2012

8/28/2012 1:25 AM EST
JANUARY – JUNE 2012 - Net sales amounted to SEK 80.8 million (64.9) - EBITDA was SEK -20.2 million (-9.2) - Earnings per share totaled SEK -0.72 (-0.48) before dilution APRIL – JUNE 2012 - Net sales amounted to SEK 38.6 million (37.5) - EBITDA was SEK -13.4 million (-5.5) - Earnings per share totaled SEK -0.42 (-0.31) before dilution HIGHLIGHTS German rebates and price adjustments from last three quarters charged...

New share issues provide Bluefish Pharmaceuticals with SEK 79 million

7/25/2012 9:41 AM EST
The Swedish generic pharmaceuticals company Bluefish has successfully completed three new share issues, which in total provides the company with SEK 79 million. By securing liquidity and improving the financial strength, the company creates the conditions necessary for continued stable growth and opportunities for gradually extending the range of niche products within more narrow disease areas and for regional...

Interim report January-March 2012

5/22/2012 8:50 AM EST
· Net sales amounted to SEK 42.2 million (27.5) · EBITDA was SEK -6.8 million (-3.6) · Earnings per share totaled SEK -0.29 (-0.17) before dilution HIGHLIGHTS Continued top-line growth · Net sales increased by 54% compared to Q1 2011 · A larger portfolio together with growing market shares behind growth in net sales Gross margin affecting EBITDA profitability · Seeking to improve the gross margin...

Year-end Report 2011

5/8/2012 9:15 AM EST
JANUARY – DECEMBER 2011 - Net sales amounted to SEK 145.2 million (92.7) - EBITDA was SEK -20.1 million (-6.8) - Earnings per share totaled SEK -1.09 (-0.60) before dilution OCTOBER – DECEMBER 2011 - Net sales amounted to SEK 41.6 million (27.8) - EBITDA was SEK -6.6 million (-2.2) - Earnings per share totaled SEK -0.33 (-0.16) before dilution HIGHLIGHTS Continued top-line growth - Net sales increased by 57%...

Bluefish continues its expansion – new share issue brings in SEK 75 million

4/24/2012 1:40 AM EST
Securing liquidity and gradually extending the range of niche products
The pharmaceuticals company, Bluefish Pharmaceuticals AB, which focuses on generic products, is carrying out a new share issue in the amount of SEK 75 million. By securing liquidity, the company will create the conditions necessary for continued stable growth and opportunities for gradually extending the range of niche products within more...

Bluefish expands product portfolio further

12/30/2011 5:34 AM EST
Bluefish has signed a new license agreement for another 15 products. The portfolio now consists of 83 products, whereof 44 have been launched. The new products belong to a variety of therapeutic categories, including cardiovascular disease, depression, viral disease, oncology, inflammation and gastrointestinal disease, with an aggregated market value in the EU of SEK 46 billion.

Bluefish completes directed new share issue – provides SEK 19.5 million

12/27/2011 3:30 AM EST
The Board of Directors in Bluefish Pharmaceuticals AB (Bluefish) has decided to complete a directed new share issue to Whochford Holding (Whochford) equivalent to SEK 19.5 million. The decision is conditioned by the general meeting’s subsequent approval. After the new share issue, Whochford will hold 7.1% of the capital and votes in Bluefish.

”Whochford is an investment company in South Asia that is well...

Bluefish Pharmaceuticals AB

RSS

Bluefish Pharmaceuticals AB is a Swedish pharmaceutical company that licenses, develops, manufactures and markets mainly generic pharmaceutical products. Low prices are maintained through efficient production and distrib...

View more


  CONTACT